What is Eli Lilly's zepbound — revenue?

Eli Lilly (LLY) reported zepbound — revenue of $4.16B in Q1 2026.

How has Eli Lilly's zepbound — revenue changed year-over-year?

Eli Lilly's zepbound — revenue increased by 79.9% year-over-year, from $2.31B to $4.16B.

What does zepbound — revenue mean?

This metric represents the total gross sales generated from the specific pharmaceutical product line indicated, net of returns, allowances, and rebates. It reflects the market adoption and commercial success of the therapeutic agent within its designated clinical indication. This figure is a critical indicator of the product's contribution to the company's overall top-line growth and its competitive positioning in the cardiometabolic market.

Eli Lilly LLY Zepbound — Revenue

Other product segments

Mounjaro

$8.66B+125%

Verzenio

$1.3B+12.3%

Jardiance

$1.11B+9.9%

Other oncology

$966M+22.4%

Trulicity

$919M-16.1%

Other cardiometabolic health

$905M-4.2%

Taltz

$733M-3.8%

Other immunology

$470M+44.2%

Neuroscience

$382M+40.4%

Similar metrics at other companies

BMYZeposia — Total Revenues

$118M+10.3%

JAZZZepzelca — Revenue from Contract with Customer, Excluding Assessed Tax

$101M+60.3%

OGNZetia — Revenue

$87M+2.4%

ARQTZORYVE foam — Product revenue, net

$49.63M+64.1%

BHCProduct sales — Revenue

$2.5B+12.3%

ARDXXPHOZAH — Total revenues

$23.3M-0.5%

Other financials

Income statement

See full

Revenue$19.8B+55.5%

Gross profit$16.2B+54.4%

Net income$7.4B+168%

EPS (diluted)$8.26+170%

Balance sheet

See full

Cash & equivalents$5.3B+70.8%

Total debt$43.4B+12.6%

Total equity$31.2B+97.9%

Total assets$116.58B+30.4%

Cash flow

See full

Operating cash flow$5.3B+220%

CapEx$2.3B+54.0%

Free cash flow$3.0B+1,828%

Valuation

See full

Market cap$1.09T+56.4%

Enterprise value$1.12T+53.8%

P/E42.9×-7.3×

P/S15×+2.0×

Profitability

See full

Gross margin82.8%+1.1pp

Net margin35%+12.3pp

FCF margin16.4%+8.7pp

Returns & leverage

See full

Return on equity107.6%+29.9pp

Debt / equity1.4×-1.1×

Current ratio1.5×+0.1×

Where this comes from

Reported directly by Eli Lilly in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eli Lilly's zepbound — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Eli Lilly's zepbound — revenue?: Eli Lilly (LLY) reported zepbound — revenue of $4.16B in Q1 2026.
How has Eli Lilly's zepbound — revenue changed year-over-year?: Eli Lilly's zepbound — revenue increased by 79.9% year-over-year, from $2.31B to $4.16B.
What does zepbound — revenue mean?: This metric represents the total gross sales generated from the specific pharmaceutical product line indicated, net of returns, allowances, and rebates. It reflects the market adoption and commercial success of the therapeutic agent within its designated clinical indication. This figure is a critical indicator of the product's contribution to the company's overall top-line growth and its competitive positioning in the cardiometabolic market.